This article is more than 5 years old. Information may no longer be current.

Lux Biosciences begins phase 3 trials of cyclosporine A implant

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JERSEY CITY, N.J. — Lux Biosciences has begun treating patients in two phase 3 clinical trials of LX201, a cyclosporine A-eluting implant, the company announced in a press release.

LX201 is a silicone matrix ocular implant, placed within the subconjunctival space, that steadily releases therapeutic doses of cyclosporine A locally for 1 year. Lux Biosciences is evaluating the device for preventing corneal transplant rejection. The two trials are investigating the efficacy of LX201 in patients at elevated immune mediated risk of corneal transplant graft rejection or loss, according to the release.

The company expects to enroll more than 400 patients in the trials, which are being conducted at approximately 35 centers in North America, Europe and India. Outcome measures include signs of rejection, such as increased corneal thickness or inflammation, and graft loss, at 1 year follow-up, the release said.